Increased rituximab (R) doses and effect on risk of elderly male patients with aggressive CD20+B-cell lymphomas: Results from the SEXIE-R-CHOP-14 trial of the DSHNHL.

被引：8

作者：

Pfreundschuh, Michael

Held, Gerhard

Zeynalova, Samira

Zwick, Carsten

Haenel, Mathias

Truemper, Lorenz

Dreyling, Martin H.

Dierlamm, Judith

Loeffler, Markus

Schmitz, Norbert

Murawski, Niels

机构：

[1] Saarland Univ Med Sch, Homburg, Germany

[2] Univ Leipzig, Inst Med Informat Stat & Epidemiol, D-04109 Leipzig, Germany

[3] Chemnitz Hosp, Chemnitz, Germany

[4] Univ Med Goettingen, Gottingen, Germany

[5] Univ Hosp Grosshadern, Munich, Germany

[6] Univ Med Ctr Hamburg Eppendorf, Hamburg, Germany

[7] Asklepios Hosp St Georg, Hamburg, Germany

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 15期

关键词：

D O I：

10.1200/jco.2014.32.15_suppl.8501

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

8501

引用

页数：1

共 48 条

[1] INCREASED RITUXIMAB (R) DOSES ELIMINATE INCREASED RISK AND IMPROVE OUTCOME OF ELDERLY MALE PATIENTS WITH AGGRESSIVE CD20+B-CELL LYMPHOMAS: THE SEXIE-R-CHOP-14 TRIAL OF THE DSHNHL
Pfreundschuh, M.
Held, G.
Zeynalova, S.
Zwick, C.
Haenel, M.
Truemper, L.
Dreyling, M. H.
Dierlamm, J.
Loeffler, M.
Schmitz, N.
Murawski, N.
HAEMATOLOGICA, 2014, 99 : 524 - 525
[2] Increased rituximab (R) doses eliminate increased risk and improve outcome of elderly male patients with aggressive CD20+B-cell lymphomas: The SEXIE-R-CHOP-14 trial of the DSHNHL
Held, G.
Murawski, N.
Zeynalova, S.
Zwick, C.
Haenel, M.
Truemper, L.
Dreyling, M.
Dierlamm, J.
Loeffler, M.
Schmitz, N.
Pfreundschuh, M.
ONCOLOGY RESEARCH AND TREATMENT, 2014, 37 : 35 - 35
[3] Increased Rituximab (R) Doses Eliminate Increased Risk and Improve Outcome of Elderly Male Patients With Aggressive CD20+ B-Cell Lymphomas: the SEXIE-R-CHOP-14 Trial of the DSHNHL
不详
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2014, 12 (08) : 8 - 9
[4] Improved outcome of elderly DLBCL patients with 6xCHOP-14 and 8 rituximab (R) applications given over an extended period (SMARTE-R-CHOP-14 Trial of the DSHNHL) is due to better results of male patients
Murawski, N.
Held, G.
Zeynalova, S.
Mueller, C.
Poeschel, V
Viardot, A.
Haenel, M.
Keller, U.
Reiser, M.
Ziepert, M.
Schmitz, N.
Pfreundschuh, M.
ONKOLOGIE, 2012, 35 : 85 - 85
[5] IMPROVED OUTCOME OF ELDERLY DLBCL PATIENTS WITH 6XCHOP-14 AND 8 RITUXIMAB (R) APPLICATIONS GIVEN OVER AN EXTENDED PERIOD (SMARTE-R-CHOP-14 DSHNHL TRIAL) IS DUE TO BETTER RESULTS OF MALE PATIENTS
Murawski, N.
Held, G.
Zeynalova, S.
Mueller, C.
Poeschel, V.
Viardot, A.
Haenel, M.
Keller, U.
Reiser, M.
Ziepert, M.
Schmitz, N.
Pfreundschuh, M.
HAEMATOLOGICA, 2012, 97 : 92 - 92
[6] Outcome of elderly patients with diffuse large B-cell lymphoma treated with R-CHOP: results from the UK NCRI R-CHOP14v21 trial with combined analysis of molecular characteristics with the DSHNHL RICOVER-60 trial
Kuhnl, A.
Cunningham, D.
Counsell, N.
Hawkes, E. A.
Qian, W.
Smith, P.
Chadwick, N.
Lawrie, A.
Mouncey, P.
Jack, A.
Pocock, C.
Ardeshna, K. M.
Radford, J.
McMillan, A.
Davies, J.
Turner, D.
Kruger, A.
Johnson, P. W.
Gambell, J.
Rosenwald, A.
Ott, G.
Horn, H.
Ziepert, M.
Pfreundschuh, M.
Linch, D.
ANNALS OF ONCOLOGY, 2017, 28 (07) : 1540 - 1546
[7] Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas:: a randomised controlled trial (RICOVER-60)
Pfreundschuh, Michael
Schubert, Joerg
Ziepert, Marita
Schmits, Rudolf
Mohren, Martin
Lengfelder, Eva
Reiser, Marcel
Nickenig, Christina
Clemens, Michael
Peter, Norma
Bokemeyer, Carsten
Eimermacher, Hartmut
Ho, Anthony
Hoffmann, Martin
Mertelsmann, Roland
Truemper, Lorenz
Balleisen, Leopold
Liersch, Ruediger
Metzner, Bernd
Hartmann, Frank
Glass, Bertram
Poeschel, Viola
Schmitz, Norbert
Ruebe, Christian
Feller, Alfred C.
Loeffler, Markus
LANCET ONCOLOGY, 2008, 9 (02): : 105 - 116
[8] Doubling rituximab in high-risk patients with aggressive B-cell lymphoma -results of the DENSE-R-MegaCHOEP trial
Friedrichs, Birte
Nickelsen, Maike
Ziepert, Marito
Altmann, Bettina
Haenel, Mathias
Viardot, Andreas
Schmidt, Christian
Ruebe, Christian
Loeffler, Markus
Pfreundschuh, Michael
Rosenwald, Andreas
Glass, Bertram
Lenz, Georg
Schmitz, Norbert
BRITISH JOURNAL OF HAEMATOLOGY, 2019, 184 (05) : 760 - 768
[9] Dose-dense CHOP plus rituximab (R-CHOP14) for the treatment of elderly patients with high-risk diffuse large B cell lymphoma: A pilot study
Rigacci, L
Nassi, L
Alterini, R
Carrai, V
Longo, G
Bernardi, F
Martini, V
Bosi, A
ACTA HAEMATOLOGICA, 2006, 115 (1-2) : 22 - 27
[10] Six versus eight doses of rituximab in patients with aggressive B cell lymphoma receiving six cycles of CHOP: results from the "Positron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin Lymphomas" (PETAL) trial
Huettmann, Andreas
Rekowski, Jan
Mueller, Stefan P.
Hertenstein, Bernd
Franzius, Christiane
Mesters, Rolf
Weckesser, Matthias
Kroschinsky, Frank
Kotzerke, Joerg
Ganser, Arnold
Bengel, Frank M.
La Rosee, Paul
Freesmeyer, Martin
Hoeffkes, Heinz-Gert
Hertel, Andreas
Behringer, Dirk
Prange-Krex, Gabriele
Griesshammer, Martin
Holzinger, Jens
Wilop, Stefan
Krohn, Thomas
Raghavachar, Aruna
Maschmeyer, Georg
Brink, Ingo
Schroers, Roland
Gaska, Tobias
Bernhard, Helga
Giagounidis, Aristoteles
Schuette, Jochen
Dienst, Ariane
Hautzel, Hubertus
Naumann, Ralph
Klein, Alfred
Hahn, Dennis
Poepperl, Gabriele
Grube, Matthias
Marienhagen, Joerg
Schwarzer, Andreas
Kurch, Lars
Hoehler, Thomas
Steiniger, Heike
Nueckel, Holger
Suedhoff, Thomas
Roemer, Wolfgang
Brinkmann, Marcus
Ose, Claudia
Alashkar, Ferras
Schmitz, Christine
Duerig, Jan
Hoelzer, Dieter
ANNALS OF HEMATOLOGY, 2019, 98 (04) : 897 - 907

← 1 2 3 4 5 →